Repligen (RGEN -0.5%) slips after its Q4 EPS misses estimates. Revenue jumped 160% Y/Y however,...

|About: Repligen Corporation (RGEN)|By:, SA News Editor

Repligen (RGEN -0.5%) slips after its Q4 EPS misses estimates. Revenue jumped 160% Y/Y however, led by strength in its bioprocessing business and higher royalty revenue from Bristol-Myers Squibb (BMY) and Pfizer (PFE). looking forward, the company see FY13 net income coming in around $18M - $20M.